Costs of non-metastatic prostate cancer treatment among privately insured men in the United States
These cost estimates support non-metastatic prostate cancer treatment related cost transparency. These estimates can help researchers evaluate costs and facilitate patient-clinician cost conversations.
Authors
- Su‐Hsin Chang (ORCID: https://orcid.org/0000-0001-5872-9556)
- Allison J. L’Hotta (ORCID: https://orcid.org/0000-0001-7825-2492)
- Hannah Rice (ORCID: https://orcid.org/0000-0001-6132-9334)
- Mary C. Politi (ORCID: https://orcid.org/0000-0001-9103-6495)
- Ashley J. Housten (ORCID: https://orcid.org/0000-0002-7379-0678)
- Bettina F. Drake (ORCID: https://orcid.org/0000-0001-9340-5848)
- Eric H. Kim (ORCID: https://orcid.org/0000-0002-0284-8342)
- Joanna L. Buss
Institutions
- University of Nevada, Reno (US)
- Washington University in St. Louis (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1371/journal.pone.0324902
- Citations
- 1
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.13
Funders
- Robert Wood Johnson Foundation
- National Center for Advancing Translational Sciences
- Cancer Moonshot